RIDASCREEN® Anti-IFX Antibodies
Intended use:RIDASCREEN® Anti-IFX Antibodies is an enzyme linked immunoassay intended for the quantitative determination of antibodies to infliximab (ATI) in human serum and plasma. Key features [...]
Dear customers,
we have started to provide the documents for our products in an electronic format. These are the Instructions for Use (IFU), the Safety Data Sheets (SDS) and the Certificate of Analysis (CoA). For batches placed on the market after 01 January 2023, you can find our documents on the eIFU portal https://eifu.r-biopharm.com.
Vedolizumab: New option for IBD patients
If conventional IBD treatments aren’t working, vedolizumab is an alternative. Therapeutic drug monitoring helps improve treatment success with vedolizumab.